Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Vascular disease

Vascular disease

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Vascular disease

19 trials tracked for Vascular disease: 7 in phase 3 or 4.

19Trials tracked
7Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 4 Phase 3 3 Phase 2 1 Phase 1 1 Other / NA 10
  1. Phase 4 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort Completed
  2. Phase 4 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed
  3. Phase 4 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Completed
  4. Phase 4 XIENCE V: SPIRIT WOMEN Sub-study Completed
  5. Phase 3 SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Completed
  6. Phase 3 Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) Completed
Show 13 more trials
  1. Phase 3 ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial Completed
  2. Phase 2 LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis Completed
  3. Phase 1 Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA) Completed
  4. N/A A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population Completed
  5. N/A XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study Completed
  6. N/A TX2® Low Profile TAA Endovascular Graft Completed
  7. N/A In-Stent Restenosis Post-Approval Study Completed
  8. N/A Transferability and Cost-effectiveness of PROSPECT in Surgical Trainees Completed
  9. N/A Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease Completed
  10. N/A XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan Completed
  11. N/A XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) Completed
  12. N/A EXCEL Clinical Trial Completed
  13. N/A XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
LLM chatbots provide varying quality and clinical risk signals for vascular disease management information
Primary Care & Family Medicine Guideline
LLM chatbots provide varying quality and clinical risk signals for vascular disease management information Chatbots show varying quality when giving advice on vascular disease
This guideline-based cross-sectional benchmark study evaluates the quality, readability, and clinical-risk signals of 110 responses from fiv…
New research shows that AI chatbots provide inconsistent and varying quality of information when answering questions about vascular disease …
Frontiers Sep 12, 2026